Terms: = Leukemia AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
136 results:
1. Construction and experimental validation of a novel ferroptosis-related gene signature for myelodysplastic syndromes.
Zhu Y; He J; Wei R; Liu J
Immun Inflamm Dis; 2024 Apr; 12(4):e1221. PubMed ID: 38578040
[TBL] [Abstract] [Full Text] [Related]
2. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract] [Full Text] [Related]
3. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract] [Full Text] [Related]
4.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
5. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
[TBL] [Abstract] [Full Text] [Related]
6. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic leukemia Relapsing after First-Line treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract] [Full Text] [Related]
7. Synchronous T-lymphoblastic lymphoma and neuroblastoma in a 3-yr-old with novel germline
Tibout P; Livingston J; Kanwar N; Yuki KE; Shlien A; Ngan B; Irwin MS; Morgenstern DA; Hitzler J; Villani A; Cohen-Gogo S
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37932047
[TBL] [Abstract] [Full Text] [Related]
8. MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases.
Zheng Z; Chen X; Zhang Y; Ren F; Ma Y
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37921060
[TBL] [Abstract] [Full Text] [Related]
9. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.
Bonnet S; Carillo S; Legrand B; Burroni B; Lavabre-Bertrand T; Requirand G; Robert N; Fornero L; Al Mansoori A; Moreaux J; Cartron G; Gabellier L; Herbaux C
Eur J Haematol; 2024 Mar; 112(3):475-478. PubMed ID: 37918825
[TBL] [Abstract] [Full Text] [Related]
10. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-ezh2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A; Singh S; Xu-Monette ZY; Coyle KM; Hilton LK; Chavdoula E; Ranganathan P; Jain N; Hanel W; Tsichlis P; Alinari L; Peterson BR; Tao J; Muthusamy N; Baiocchi R; Epperla N; Young KH; Morin R; Sehgal L
Leukemia; 2023 Oct; 37(10):2094-2106. PubMed ID: 37598282
[TBL] [Abstract] [Full Text] [Related]
11. [EZH inhibitors in lymphoma therapy].
Ishitsuka K
Rinsho Ketsueki; 2023; 64(7):665-669. PubMed ID: 37544728
[TBL] [Abstract] [Full Text] [Related]
12. Integrative Multi-Omics Analysis of Oncogenic ezh2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
Aldana J; Gardner ML; Freitas MA
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
[TBL] [Abstract] [Full Text] [Related]
13. Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
Calabresi L; Carretta C; Romagnoli S; Rotunno G; Parenti S; Bertesi M; Bartalucci N; Rontauroli S; Chiereghin C; Castellano S; Gentili G; Maccari C; Vanderwert F; Mannelli F; Della Porta M; Manfredini R; Vannucchi AM; Guglielmelli P
Am J Hematol; 2023 Oct; 98(10):1520-1531. PubMed ID: 37399248
[TBL] [Abstract] [Full Text] [Related]
14. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW; Nemirovsky D; Famulare CA; Farnoud N; Mohanty AS; Stone-Molloy ZS; Chervin J; Ball BJ; Epstein-Peterson ZD; Arcila ME; Stonestrom AJ; Dunbar A; Cai SF; Glass JL; Geyer MB; Rampal RK; Berman E; Abdel-Wahab OI; Stein EM; Tallman MS; Levine RL; Goldberg AD; Papaemmanuil E; Zhang Y; Roshal M; Derkach A; Xiao W
Blood Adv; 2023 Sep; 7(17):5000-5013. PubMed ID: 37142255
[TBL] [Abstract] [Full Text] [Related]
15. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Zhao L; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakiuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori-Kondo A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemanuil E; Miyazaki Y; Hellström-Lindberg E; Ogawa S
Blood Adv; 2023 Jul; 7(14):3624-3636. PubMed ID: 36989067
[TBL] [Abstract] [Full Text] [Related]
16. [Analysis of epigenetic modification gene mutations among patients with acute myeloid leukemia].
Wei J; Qiu H; Zhou H; Chen Z; Miao L; Wang Y; Zhao L; Cai Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Apr; 40(4):435-441. PubMed ID: 36972938
[TBL] [Abstract] [Full Text] [Related]
17. Effects of epigenetic therapy on natural killer cell function and development in hematologic malignancy.
Lordo MR; Stiff AR; Oakes CC; Mundy-Bosse BL
J Leukoc Biol; 2023 May; 113(5):518-524. PubMed ID: 36860165
[TBL] [Abstract] [Full Text] [Related]
18. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract] [Full Text] [Related]
19. Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Kurahashi Y; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Yamashita S; Hattori N; Nakamura H; Kawaguchi A; Ushijima T; Sueoka E; Kimura S
Blood Adv; 2023 Apr; 7(8):1545-1559. PubMed ID: 36516085
[TBL] [Abstract] [Full Text] [Related]
20. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract] [Full Text] [Related]
[Next]
